ST14 and breast carcinoma: One such protease is matriptase, a type II transmembrane serine protease, which was originally discovered to be an ECM-degrading enzyme in breast cancer [5] and was identified to contribute to cancer invasiveness through its actions on substrates such as cell adhesion molecules [6], ECM proteins [7,8] and growth factors [9,10].